Symbols / ALXO Stock $1.62 -5.00% ALX Oncology Holdings Inc.
ALXO (Stock) Chart
About
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 217.31M | Enterprise Value | 193.71M | Income | -101.69M | Sales | — | Book/sh | 0.48 | Cash/sh | 0.34 |
| Dividend Yield | — | Payout | 0.00% | Employees | 43 | IPO | — | P/E | — | Forward P/E | -2.63 |
| PEG | — | P/S | — | P/B | 3.38 | P/C | — | EV/EBITDA | -1.93 | EV/Sales | — |
| Quick Ratio | 1.84 | Current Ratio | 2.07 | Debt/Eq | 56.85 | LT Debt/Eq | — | EPS (ttm) | -1.90 | EPS next Y | -0.61 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-07 | ROA | -60.95% | ROE | -145.70% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 134.56M | Shs Float | 104.06M | Short Float | 1.99% |
| Short Ratio | 3.36 | Short Interest | — | 52W High | 2.66 | 52W Low | 0.40 | Beta | 0.50 | Avg Volume | 955.09K |
| Volume | 498.17K | Target Price | $4.60 | Recom | None | Prev Close | $1.70 | Price | $1.61 | Change | -5.00% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-19 | init | Wells Fargo | — → Overweight | $5 |
| 2026-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2026-02-05 | main | Piper Sandler | Overweight → Overweight | $4 |
| 2025-05-21 | main | UBS | Buy → Buy | $1 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-03-07 | main | Stifel | Hold → Hold | $2 |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-06 | main | Piper Sandler | Overweight → Overweight | $9 |
| 2025-03-06 | up | Jefferies | Hold → Buy | $3 |
| 2025-01-27 | main | UBS | Buy → Buy | $2 |
| 2025-01-24 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-01-24 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-12-19 | down | Jefferies | Buy → Hold | $2 |
| 2024-12-18 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-11-12 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-08-16 | main | UBS | Buy → Buy | $4 |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-12 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-08-09 | reit | Stifel | Hold → Hold | $3 |
- Buy or Sell? | ALX Oncology Holdings Inc. posts 0.1% EPS miss, no revenue data - Revision Downgrade - UBND thành phố Hải Phòng hu, 23 Apr 2026 08
- Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Mon, 09 Feb 2026 08
- [ARS] ALX ONCOLOGY HOLDINGS INC SEC Filing - Stock Titan Mon, 20 Apr 2026 21
- BioAffinity stock surges 113.8% in 3 months: What's driving the rally? - MSN hu, 23 Apr 2026 09
- $ALXO stock is down 11% today. Here's what we see in our data. - Quiver Quantitative hu, 09 Apr 2026 19
- ALX Oncology (NASDAQ: ALXO) awards 800,000 options to chief officer - Stock Titan Fri, 17 Apr 2026 20
- ALXO (ALX Oncology Holdings Inc.) reports narrow Q4 2025 EPS miss sending shares 0.6% lower on mild investor disappointment. - Sector Perform - UBND thành phố Hải Phòng hu, 23 Apr 2026 09
- New ALX Oncology operating chief gets 800,000-share stock option - Stock Titan Fri, 17 Apr 2026 20
- ALX ONCOLOGY ($ALXO) Releases Q4 2025 Earnings - Quiver Quantitative Fri, 27 Feb 2026 08
- ALX Oncology (ALXO) awards CMO 100,000 stock options at $1.68 - Stock Titan Fri, 17 Apr 2026 20
- [DEF 14A] ALX ONCOLOGY HOLDINGS INC Definitive Proxy Statement - Stock Titan Mon, 20 Apr 2026 20
- $150M cash boost, cancer drug trials give ALX Oncology a 2028 runway - Stock Titan Fri, 27 Feb 2026 08
- Jeff Knight named reporting insider at ALX Oncology (NASDAQ: ALXO) with no trades - Stock Titan Fri, 17 Apr 2026 20
- ALX brings in 30-year biotech veteran ahead of key cancer milestones - Stock Titan Mon, 13 Apr 2026 12
- Cancer biotech ALX Oncology lines up three investor talks - Stock Titan hu, 19 Feb 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
—
|
—
|
—
|
0.00
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
0.00
|
| Gross Profit |
|
—
|
—
|
—
|
0.00
|
| Operating Expense |
|
100.85
-29.21%
|
142.47
-16.33%
|
170.28
+33.62%
|
127.44
|
| Research And Development |
|
77.00
-33.84%
|
116.37
-17.93%
|
141.79
+44.10%
|
98.40
|
| Selling General And Administration |
|
23.85
-8.60%
|
26.09
-8.39%
|
28.48
-1.90%
|
29.04
|
| General And Administrative Expense |
|
23.85
-8.60%
|
26.09
-8.39%
|
28.48
-1.90%
|
29.04
|
| Salaries And Wages |
|
15.05
-7.25%
|
16.22
-13.29%
|
18.71
-0.83%
|
18.86
|
| Other Gand A |
|
8.80
-10.82%
|
9.87
+0.99%
|
9.78
-3.89%
|
10.17
|
| Total Expenses |
|
100.85
-29.21%
|
142.47
-16.33%
|
170.28
+33.62%
|
127.44
|
| Operating Income |
|
-100.85
+29.21%
|
-142.47
+16.33%
|
-170.28
-33.62%
|
-127.44
|
| Total Operating Income As Reported |
|
-104.02
+26.99%
|
-142.47
+16.33%
|
-170.28
-33.62%
|
-127.44
|
| EBITDA |
|
-99.39
+24.85%
|
-132.25
+16.51%
|
-158.40
-28.95%
|
-122.84
|
| Normalized EBITDA |
|
-96.21
+27.25%
|
-132.25
+16.51%
|
-158.40
-28.95%
|
-122.84
|
| Reconciled Depreciation |
|
0.71
-19.04%
|
0.87
+4.31%
|
0.84
+144.44%
|
0.34
|
| EBIT |
|
-100.09
+24.81%
|
-133.12
+16.40%
|
-159.24
-29.27%
|
-123.18
|
| Total Unusual Items |
|
-3.17
|
0.00
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-3.17
|
0.00
|
0.00
|
0.00
|
| Special Income Charges |
|
-3.17
|
0.00
|
0.00
|
0.00
|
| Write Off |
|
3.17
|
0.00
|
0.00
|
—
|
| Net Income |
|
-101.69
+24.59%
|
-134.85
+16.14%
|
-160.81
-30.23%
|
-123.48
|
| Pretax Income |
|
-101.69
+24.59%
|
-134.85
+16.14%
|
-160.81
-30.29%
|
-123.42
|
| Net Non Operating Interest Income Expense |
|
2.36
-69.07%
|
7.64
-15.93%
|
9.08
+124.85%
|
4.04
|
| Interest Expense Non Operating |
|
1.60
-7.35%
|
1.73
+10.48%
|
1.56
+557.56%
|
0.24
|
| Net Interest Income |
|
2.36
-69.07%
|
7.64
-15.93%
|
9.08
+124.85%
|
4.04
|
| Interest Expense |
|
1.60
-7.35%
|
1.73
+10.48%
|
1.56
+557.56%
|
0.24
|
| Interest Income Non Operating |
|
3.96
-57.68%
|
9.37
-12.05%
|
10.65
+148.92%
|
4.28
|
| Interest Income |
|
3.96
-57.68%
|
9.37
-12.05%
|
10.65
+148.92%
|
4.28
|
| Other Income Expense |
|
-3.21
-15955.00%
|
-0.02
-105.14%
|
0.39
+1868.18%
|
-0.02
|
| Other Non Operating Income Expenses |
|
-0.04
-80.00%
|
-0.02
-105.14%
|
0.39
+1868.18%
|
-0.02
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.06
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-101.69
+24.59%
|
-134.85
+16.14%
|
-160.81
-30.23%
|
-123.48
|
| Net Income From Continuing Operation Net Minority Interest |
|
-101.69
+24.59%
|
-134.85
+16.14%
|
-160.81
-30.23%
|
-123.48
|
| Net Income From Continuing And Discontinued Operation |
|
-101.69
+24.59%
|
-134.85
+16.14%
|
-160.81
-30.23%
|
-123.48
|
| Net Income Continuous Operations |
|
-101.69
+24.59%
|
-134.85
+16.14%
|
-160.81
-30.23%
|
-123.48
|
| Normalized Income |
|
-98.52
+26.94%
|
-134.85
+16.14%
|
-160.81
-30.23%
|
-123.48
|
| Net Income Common Stockholders |
|
-101.69
+24.59%
|
-134.85
+16.14%
|
-160.81
-30.23%
|
-123.48
|
| Diluted EPS |
|
—
|
-2.58
+31.02%
|
-3.74
-23.43%
|
-3.03
|
| Basic EPS |
|
—
|
-2.58
+31.02%
|
-3.74
-23.43%
|
-3.03
|
| Basic Average Shares |
|
—
|
52.17
+21.37%
|
42.99
+5.62%
|
40.70
|
| Diluted Average Shares |
|
—
|
52.17
+21.37%
|
42.99
+5.62%
|
40.70
|
| Diluted NI Availto Com Stockholders |
|
-101.69
+24.59%
|
-134.85
+16.14%
|
-160.81
-30.23%
|
-123.48
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
59.05
-60.04%
|
147.78
-39.08%
|
242.55
-20.86%
|
306.49
|
| Current Assets |
|
50.73
-62.24%
|
134.35
-28.79%
|
188.66
-30.38%
|
270.97
|
| Cash Cash Equivalents And Short Term Investments |
|
44.79
-64.94%
|
127.76
-30.09%
|
182.74
-31.36%
|
266.21
|
| Cash And Cash Equivalents |
|
16.37
-6.80%
|
17.57
-21.60%
|
22.41
-54.11%
|
48.82
|
| Other Short Term Investments |
|
28.42
-74.21%
|
110.19
-31.27%
|
160.33
-26.25%
|
217.38
|
| Receivables |
|
0.30
-66.59%
|
0.89
|
—
|
—
|
| Accrued Interest Receivable |
|
0.30
-66.59%
|
0.89
|
—
|
—
|
| Prepaid Assets |
|
5.62
-1.00%
|
5.68
|
—
|
—
|
| Other Current Assets |
|
0.02
-25.93%
|
0.03
-99.54%
|
5.92
+24.38%
|
4.76
|
| Total Non Current Assets |
|
8.32
-38.02%
|
13.42
-75.09%
|
53.89
+51.73%
|
35.52
|
| Net PPE |
|
3.87
-59.80%
|
9.63
-11.15%
|
10.84
+10.48%
|
9.81
|
| Gross PPE |
|
5.85
-50.03%
|
11.71
-3.06%
|
12.08
+18.23%
|
10.22
|
| Accumulated Depreciation |
|
-1.98
+4.72%
|
-2.08
-67.91%
|
-1.24
-206.95%
|
-0.40
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.63
-1.88%
|
0.64
+10.00%
|
0.58
+13.73%
|
0.51
|
| Other Properties |
|
4.52
-47.26%
|
8.56
-4.71%
|
8.98
+22.31%
|
7.35
|
| Leases |
|
0.71
-71.74%
|
2.51
-0.16%
|
2.51
+6.48%
|
2.36
|
| Investments And Advances |
|
3.49
-0.85%
|
3.52
-90.05%
|
35.41
+112.05%
|
16.70
|
| Non Current Accounts Receivable |
|
—
|
—
|
—
|
0.08
|
| Non Current Prepaid Assets |
|
0.80
+1100.00%
|
0.07
-99.10%
|
7.44
-14.66%
|
8.72
|
| Other Non Current Assets |
|
0.15
-25.50%
|
0.20
+0.00%
|
0.20
-30.56%
|
0.29
|
| Total Liabilities Net Minority Interest |
|
33.06
-3.20%
|
34.16
-35.36%
|
52.84
+22.81%
|
43.02
|
| Current Liabilities |
|
24.55
+32.72%
|
18.50
-48.61%
|
36.00
+27.10%
|
28.32
|
| Payables And Accrued Expenses |
|
12.66
+24.26%
|
10.19
-63.27%
|
27.73
+22.87%
|
22.57
|
| Payables |
|
4.91
+5.77%
|
4.65
-49.14%
|
9.13
-6.06%
|
9.72
|
| Accounts Payable |
|
4.91
+9.27%
|
4.50
-47.65%
|
8.59
+6.42%
|
8.07
|
| Other Payable |
|
—
|
—
|
—
|
—
|
| Current Accrued Expenses |
|
7.74
+39.77%
|
5.54
-70.21%
|
18.59
+44.78%
|
12.84
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.36
-17.90%
|
5.31
-12.54%
|
6.07
+63.62%
|
3.71
|
| Total Tax Payable |
|
—
|
—
|
—
|
—
|
| Income Tax Payable |
|
—
|
—
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
5.22
+1099.31%
|
0.43
-72.38%
|
1.57
+51.30%
|
1.04
|
| Current Debt |
|
5.22
+1099.31%
|
0.43
|
—
|
—
|
| Other Current Borrowings |
|
5.22
+1099.31%
|
0.43
|
—
|
—
|
| Current Capital Lease Obligation |
|
—
|
—
|
1.57
+51.30%
|
1.04
|
| Other Current Liabilities |
|
2.32
-9.72%
|
2.57
+16.69%
|
2.21
+7.56%
|
2.05
|
| Total Non Current Liabilities Net Minority Interest |
|
8.51
-45.63%
|
15.66
-7.02%
|
16.84
+14.56%
|
14.70
|
| Long Term Debt And Capital Lease Obligation |
|
4.53
-52.14%
|
9.47
-1.76%
|
9.64
+2.66%
|
9.39
|
| Long Term Debt |
|
4.53
-52.14%
|
9.47
-1.76%
|
9.64
+2.66%
|
9.39
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
5.98
|
—
|
| Other Non Current Liabilities |
|
3.98
-35.68%
|
6.19
-14.07%
|
7.20
+35.59%
|
5.31
|
| Stockholders Equity |
|
25.98
-77.13%
|
113.62
-40.11%
|
189.71
-27.99%
|
263.46
|
| Common Stock Equity |
|
25.98
-77.13%
|
113.62
-40.11%
|
189.71
-27.99%
|
263.46
|
| Capital Stock |
|
0.05
+1.89%
|
0.05
+6.00%
|
0.05
+21.95%
|
0.04
|
| Common Stock |
|
0.05
+1.89%
|
0.05
+6.00%
|
0.05
+21.95%
|
0.04
|
| Share Issued |
|
54.39
+2.52%
|
53.05
+6.21%
|
49.95
+22.25%
|
40.86
|
| Ordinary Shares Number |
|
54.39
+2.52%
|
53.05
+6.21%
|
49.95
+22.25%
|
40.86
|
| Additional Paid In Capital |
|
748.72
+1.95%
|
734.41
+8.69%
|
675.68
+14.57%
|
589.74
|
| Retained Earnings |
|
-722.82
-16.37%
|
-621.12
-27.73%
|
-486.27
-49.41%
|
-325.47
|
| Gains Losses Not Affecting Retained Earnings |
|
0.03
-89.82%
|
0.28
+7.42%
|
0.26
+130.30%
|
-0.84
|
| Other Equity Adjustments |
|
0.03
-89.82%
|
0.28
+7.42%
|
0.26
+130.30%
|
-0.84
|
| Total Equity Gross Minority Interest |
|
25.98
-77.13%
|
113.62
-40.11%
|
189.71
-27.99%
|
263.46
|
| Total Capitalization |
|
30.51
-75.21%
|
123.09
-38.26%
|
199.35
-26.94%
|
272.85
|
| Working Capital |
|
26.17
-77.41%
|
115.85
-24.11%
|
152.66
-37.09%
|
242.64
|
| Invested Capital |
|
35.73
-71.07%
|
123.52
-38.04%
|
199.35
-26.94%
|
272.85
|
| Total Debt |
|
9.75
-1.57%
|
9.90
+2.75%
|
9.64
+2.66%
|
9.39
|
| Capital Lease Obligations |
|
—
|
—
|
7.56
+626.03%
|
1.04
|
| Net Tangible Assets |
|
25.98
-77.13%
|
113.62
-40.11%
|
189.71
-27.99%
|
263.46
|
| Tangible Book Value |
|
25.98
-77.13%
|
113.62
-40.11%
|
189.71
-27.99%
|
263.46
|
| Available For Sale Securities |
|
3.49
-0.85%
|
3.52
-90.05%
|
35.41
+112.05%
|
16.70
|
| Dueto Related Parties Current |
|
0.00
-100.00%
|
0.15
-72.56%
|
0.54
-67.09%
|
1.65
|
| Investmentin Financial Assets |
|
3.49
-0.85%
|
3.52
-90.05%
|
35.41
+112.05%
|
16.70
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-84.14
+30.98%
|
-121.91
+6.48%
|
-130.36
-46.11%
|
-89.22
|
| Cash Flow From Continuing Operating Activities |
|
-84.14
+30.98%
|
-121.91
+6.48%
|
-130.36
-46.11%
|
-89.22
|
| Net Income From Continuing Operations |
|
-101.69
+24.59%
|
-134.85
+16.14%
|
-160.81
-30.23%
|
-123.48
|
| Depreciation Amortization Depletion |
|
0.71
-19.04%
|
0.87
+4.31%
|
0.84
+144.44%
|
0.34
|
| Depreciation And Amortization |
|
0.71
-19.04%
|
0.87
+4.31%
|
0.84
+144.44%
|
0.34
|
| Other Non Cash Items |
|
2.00
-2.49%
|
2.05
+34.69%
|
1.52
+30.31%
|
1.17
|
| Stock Based Compensation |
|
12.58
-53.57%
|
27.09
+3.12%
|
26.27
+10.21%
|
23.84
|
| Asset Impairment Charge |
|
3.17
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
—
|
0.01
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.01
|
0.00
|
0.00
|
| Change In Working Capital |
|
0.34
+102.70%
|
-12.43
-249.81%
|
8.30
-15.77%
|
9.85
|
| Change In Receivables |
|
—
|
—
|
—
|
0.00
|
| Change In Prepaid Assets |
|
0.66
+195.09%
|
-0.69
+46.40%
|
-1.29
+12.53%
|
-1.48
|
| Change In Payables And Accrued Expense |
|
2.27
+113.34%
|
-17.04
-261.15%
|
10.57
-8.47%
|
11.55
|
| Change In Accrued Expense |
|
2.00
+115.86%
|
-12.62
-212.47%
|
11.22
+59.73%
|
7.03
|
| Change In Payable |
|
0.27
+106.16%
|
-4.42
-580.74%
|
-0.65
-114.34%
|
4.53
|
| Change In Account Payable |
|
0.27
+106.16%
|
-4.42
-580.74%
|
-0.65
-114.34%
|
4.53
|
| Change In Other Current Assets |
|
-0.69
-109.30%
|
7.38
+439.90%
|
1.37
+82.13%
|
0.75
|
| Change In Other Current Liabilities |
|
-1.91
+7.77%
|
-2.07
+11.98%
|
-2.35
-140.84%
|
-0.98
|
| Investing Cash Flow |
|
82.59
-4.25%
|
86.26
+93.15%
|
44.66
+118.97%
|
-235.42
|
| Cash Flow From Continuing Investing Activities |
|
82.59
-4.25%
|
86.26
+93.15%
|
44.66
+118.97%
|
-235.42
|
| Net PPE Purchase And Sale |
|
-0.21
+52.57%
|
-0.45
+64.91%
|
-1.27
+10.72%
|
-1.43
|
| Purchase Of PPE |
|
-0.21
+52.57%
|
-0.45
+64.91%
|
-1.27
+10.72%
|
-1.43
|
| Capital Expenditure |
|
-0.21
+52.57%
|
-0.45
+64.91%
|
-1.27
+10.72%
|
-1.43
|
| Net Investment Purchase And Sale |
|
82.80
-4.50%
|
86.70
+88.77%
|
45.93
+119.63%
|
-233.99
|
| Purchase Of Investment |
|
-51.59
+51.96%
|
-107.41
+56.45%
|
-246.63
+34.54%
|
-376.79
|
| Sale Of Investment |
|
134.39
-30.77%
|
194.11
-33.65%
|
292.56
+104.87%
|
142.80
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
|
0.00
|
| Financing Cash Flow |
|
0.36
-98.83%
|
30.82
-48.02%
|
59.29
+501.33%
|
9.86
|
| Cash Flow From Continuing Financing Activities |
|
0.36
-98.83%
|
30.82
-48.02%
|
59.29
+501.33%
|
9.86
|
| Net Issuance Payments Of Debt |
|
-1.36
-64.93%
|
-0.83
-113.14%
|
-0.39
-104.04%
|
9.61
|
| Issuance Of Debt |
|
—
|
0.00
|
0.00
-100.00%
|
10.00
|
| Repayment Of Debt |
|
-1.36
-64.93%
|
-0.83
-113.14%
|
-0.39
+0.00%
|
-0.39
|
| Long Term Debt Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
10.00
|
| Long Term Debt Payments |
|
-1.36
-64.93%
|
-0.83
-113.14%
|
-0.39
+0.00%
|
-0.39
|
| Net Long Term Debt Issuance |
|
-1.36
-64.93%
|
-0.83
-113.14%
|
-0.39
-104.04%
|
9.61
|
| Net Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
58.89
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.04
-98.08%
|
1.98
+150.38%
|
0.79
-12.29%
|
0.90
|
| Net Other Financing Charges |
|
1.69
-94.31%
|
29.66
|
—
|
-0.66
|
| Changes In Cash |
|
-1.19
+75.33%
|
-4.84
+81.68%
|
-26.42
+91.61%
|
-314.78
|
| Beginning Cash Position |
|
17.63
-21.53%
|
22.47
-54.03%
|
48.89
-86.56%
|
363.67
|
| End Cash Position |
|
16.44
-6.77%
|
17.63
-21.53%
|
22.47
-54.03%
|
48.89
|
| Free Cash Flow |
|
-84.35
+31.06%
|
-122.36
+7.05%
|
-131.64
-45.22%
|
-90.65
|
| Interest Paid Supplemental Data |
|
1.26
-9.23%
|
1.39
+17.84%
|
1.18
+1042.72%
|
0.10
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
|
0.00
|
| Amortization Of Securities |
|
-1.24
+73.33%
|
-4.66
+28.21%
|
-6.49
-590.11%
|
-0.94
|
| Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
58.89
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
|
0.00
-100.00%
|
58.89
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-17 View
- 42026-04-17 View
- 8-K2026-04-13 View
- 42026-03-23 View
- 42026-03-23 View
- 10-K2026-03-09 View
- 42026-03-05 View
- 8-K2026-02-27 View
- 42026-02-20 View
- 42026-02-19 View
- 42026-02-04 View
- 8-K2026-01-30 View
- 8-K2026-01-30 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 8-K2026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|